Personalized neoantigen mRNA vaccine mitigates melanoma recurrence
Nature Reviews Clinical Oncology, Published online: 01 February 2024; doi:10.1038/s41571-024-00867-1Personalized neoantigen mRNA vaccine mitigates melanoma recurrence (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - February 1, 2024 Category: Cancer & Oncology Authors: David Killock Source Type: research
Sotorasib dosing and incremental cost ineffectiveness — implications and lessons for stakeholders
Nature Reviews Clinical Oncology, Published online: 30 January 2024; doi:10.1038/s41571-024-00862-6The US FDA Accelerated Approval of sotorasib required the sponsor to conduct a randomized trial that compared the safety and efficacy of the approved dose with a lower dose. These results, recently disclosed, have important implications for patients, payers, oncologists and the pharmaceutical industry. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 30, 2024 Category: Cancer & Oncology Authors: Garth W. Strohbehn Mark J. Ratain Source Type: research
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Nature Reviews Clinical Oncology, Published online: 26 January 2024; doi:10.1038/s41571-023-00852-0Various BRAF alterations are found and function as oncogenic drivers across diverse cancer types. BRAF inhibitor-based therapy has improved outcomes for patients with cancers harbouring BRAFV600 mutations, although resistance develops in most, and the current inhibitors are not effective against other types of BRAF alterations. In this Review, the authors describe the mechanisms underlying oncogenic BRAF signalling, as well as pan-cancer and lineage-specific mechanisms of intrinsic, adaptive and acquired resistance to BRAF in...
Source: Nature Reviews Clinical Oncology - January 26, 2024 Category: Cancer & Oncology Authors: Aphrothiti J. Hanrahan Ziyu Chen Neal Rosen David B. Solit Source Type: research
Combination strategies for advanced-stage urothelial carcinoma: a paradigm shift
Nature Reviews Clinical Oncology, Published online: 26 January 2024; doi:10.1038/s41571-024-00861-7Durable responses with first-line platinum-based chemotherapy for advanced-stage urothelial carcinoma are rare, and patient outcomes are poor. Recently, CheckMate 901 became the first phase III trial to establish a significant overall survival benefit from a combined chemoimmunotherapy approach in this disease setting. Herein, we discuss key findings from CheckMate 901 and their implications in the context of a rapidly evolving treatment landscape. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 26, 2024 Category: Cancer & Oncology Authors: Nimira Alimohamed Srikala S. Sridhar Source Type: research
Repotrectinib effective in ROS1-fusion-positive NSCLC
Nature Reviews Clinical Oncology, Published online: 26 January 2024; doi:10.1038/s41571-024-00864-4Repotrectinib effective in ROS1-fusion-positive NSCLC (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 26, 2024 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Harnessing neoantigen-specific T cells for precision cancer immunotherapy
Nature Reviews Clinical Oncology, Published online: 19 January 2024; doi:10.1038/s41571-024-00860-8Several novel personalized therapies focus on targeting neoantigens. Such strategies require the identification of suitable vaccine neoepitopes or neoantigen-specific T cell receptor (TCR) clonotypes. Herein, we discuss a recently published report that describes a combined transcriptional and phenotype signature, NeoTCRPBL, that enables the minimally invasive identification of rare neoantigen-specific TCRs from peripheral blood that might enable more-effective T cell-based therapies against cancer. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 19, 2024 Category: Cancer & Oncology Authors: Marco Donia Inge Marie Svane Source Type: research
Lung cancer in patients who have never smoked — an emerging disease
Nature Reviews Clinical Oncology, Published online: 09 January 2024; doi:10.1038/s41571-023-00844-0Lung cancer is a disease typically associated with tobacco smoking; however, lung cancer in individuals who have never smoked (LCINS) is estimated to be the fifth most common cause of cancer-related deaths globally. Moreover, smoking rates are declining around the world and therefore LCINS is likely to increase as a proportion of all lung cancers over time. Thus, understanding the aetiology and features of LCINS is increasingly important. Herein, the authors review the emerging data on the epidemiology, clinical characteristi...
Source: Nature Reviews Clinical Oncology - January 9, 2024 Category: Cancer & Oncology Authors: Jaclyn LoPiccolo Alexander Gusev David C. Christiani Pasi A. J änne Source Type: research
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives
Nature Reviews Clinical Oncology, Published online: 08 January 2024; doi:10.1038/s41571-023-00849-9The discovery of ERBB2 as a gene frequently amplified and/or overexpressed in breast cancers and of its product HER2 as a biomarker has spurred the development of various targeted therapies. As a result, the prognosis of patients with advanced-stage HER2-positive breast cancer has greatly improved in the past decades. The authors of this Review describe the development of the current treatment landscape for these patients and discuss how to address resistance to further improve outcomes. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 8, 2024 Category: Cancer & Oncology Authors: Antonio Marra Sarat Chandarlapaty Shanu Modi Source Type: research
Myeloid-derived suppressor cells in cancer and cancer therapy
Nature Reviews Clinical Oncology, Published online: 08 January 2024; doi:10.1038/s41571-023-00846-yMyeloid-derived suppressor cells (MDSCs) are a heterogeneous population of myeloid cells that accumulate in the tumour microenvironment, where they exert various immunosuppressive mechanisms as well as a variety of other tumour-promoting effects. Herein, the authors provide an overview of MDSC generation and their accumulation in tumours, describe the interplay between MDSCs and various other cell types found in tumours, and review the mechanisms by which MDSCs promote tumour development and progression, metastasis, and resis...
Source: Nature Reviews Clinical Oncology - January 8, 2024 Category: Cancer & Oncology Authors: Samantha A. Lasser Feyza G. Ozbay Kurt Ihor Arkhypov Jochen Utikal Viktor Umansky Source Type: research
Exploring the next generation of antibody–drug conjugates
Nature Reviews Clinical Oncology, Published online: 08 January 2024; doi:10.1038/s41571-023-00850-2Antibody–drug conjugates (ADCs) are effective cancer drugs that have been approved for more than 20 specific indications. Nonetheless, acquired resistance and adverse events both limit the effectiveness of these agents. In this Review, the authors describe the development of novel ADC designs, including bispecific ADCs, probody–drug conjugates, immune-stimulating ADCs, protein-degrader ADCs and dual-drug ADCs. all of which have the potential to address these challenges and provide more effective ADCs. (Source: Nature Revi...
Source: Nature Reviews Clinical Oncology - January 8, 2024 Category: Cancer & Oncology Authors: Kyoji Tsuchikama Yasuaki Anami Summer Y. Y. Ha Chisato M. Yamazaki Source Type: research
Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma
Nature Reviews Clinical Oncology, Published online: 08 January 2024; doi:10.1038/s41571-023-00848-wDespite dramatic progress over the past decade, only around 50% of patients with advanced-stage melanoma derive durable benefit from immune-checkpoint inhibitors (ICIs) and/or BRAF and MEK (BRAF/MEK) inhibitors. Over the past few years, adoptive cell therapy with tumour-infiltrating lymphocytes (TILs) has demonstrated encouraging efficacy including in patients with disease progression on ICIs or BRAF/MEK inhibitors. In this Review, the authors summarize the role of TIL therapies in the management of these patients and describ...
Source: Nature Reviews Clinical Oncology - January 8, 2024 Category: Cancer & Oncology Authors: Sebastian Klobuch Tom T. P. Seijkens Ton N. Schumacher John B. A. G. Haanen Source Type: research
‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent
Nature Reviews Clinical Oncology, Published online: 05 January 2024; doi:10.1038/s41571-023-00857-9The FDA approval of perioperative pembrolizumab, an approach that combines neoadjuvant and adjuvant therapy with this agent, for patients with early stage non-small-cell lung cancer (NSCLC) contradicts its own stated standard for combination therapies. Given the large population of patients with early stage NSCLC and the high costs of pembrolizumab, whether the adjuvant component provides incremental benefit is an important question. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 5, 2024 Category: Cancer & Oncology Authors: Garth W. Strohbehn Bishal Gyawali Source Type: research
Benefit with MRD-guided treatment in CLL
Nature Reviews Clinical Oncology, Published online: 02 January 2024; doi:10.1038/s41571-023-00858-8Benefit with MRD-guided treatment in CLL (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 2, 2024 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Optimizing the FDA’s Project Optimus: opportunities and challenges
Nature Reviews Clinical Oncology, Published online: 21 December 2023; doi:10.1038/s41571-023-00853-zThrough Project Optimus, the FDA calls for radical changes in the design of early phase trials to identify the optimal doses of oncology drugs to achieve maximal efficacy with better tolerability and patient acceptability. Herein, we discuss approaches that will enable the implementation of this initiative as well as some concerns that the draft guidance has raised in the oncology community. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - December 21, 2023 Category: Cancer & Oncology Authors: Simon Rodney Udai Banerji Source Type: research
PERSEUS triumphs — efficacy of daratumumab confirmed in transplant-eligible NDMM
Nature Reviews Clinical Oncology, Published online: 20 December 2023; doi:10.1038/s41571-023-00856-wPERSEUS triumphs — efficacy of daratumumab confirmed in transplant-eligible NDMM (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - December 20, 2023 Category: Cancer & Oncology Authors: David Killock Source Type: research
